Cancers Submission Guide: MDPI Process (2026)

Cancers is not a stronger version of a subscription oncology journal, and it is not a weaker one. It is a different model. MDPI built it around speed and soundness-based review: the editorial question is whether the work is methodologically sound and within scope, not whether it ranks among the most selective findings of the year. That model shapes everything about how you should prepare the package.

Two consequences matter most. First, the journal is section-based and organized by oncology subfield, so scope fit is assessed against a specific section rather than a vague "is this interesting" bar. Second, the pre-check is fast and partly template-driven, so completeness is rewarded and incompleteness is punished early. A technically excellent manuscript with a missing ethics statement can be returned before a reviewer ever sees it, while a competent, complete, in-scope study moves quickly.

The unusual upside: Cancers explicitly accepts studies reporting meaningful negative results, a category subscription oncology titles routinely desk-reject. If your study is a well-powered null result with clinical or biological relevance, this is one of the few oncology venues where that is a feature rather than a liability.

The core fit for most submissions is the original research article. It works best when the cancer question is central, the methods are reproducible from the text, and the declarations and reporting package are complete on first upload.

Ask these questions before you submit:

• is the cancer question the actual subject of the paper, or is cancer a downstream application of a general-biology finding?
• can a reader reproduce the methods from the manuscript and supplementary files alone?
• are the ethics, consent, and data statements complete and specific, or are they still stub text?
• does the reporting follow the checklist that matches the study design?

If the answers are uncertain, the pre-check problem is usually more important than the science problem.

The pre-check editor is answering a short list of questions fast.

On scope, the editor asks whether the manuscript belongs in an oncology journal and in which section. If the cancer relevance is thin or bolted on, the paper is redirected or returned. On soundness, the question is whether the methods are reproducible and the analysis appropriate. Cancers does not require the finding to be field-defining, but it does require the work to be done correctly and reported in full.

On integrity, the editor checks whether ethics approvals, consent, image-integrity expectations, and data availability are all in order. MDPI runs integrity and plagiarism checks at pre-check, and gaps here trigger fast returns. On completeness, the editor looks for the declarations block. A manuscript missing Author Contributions, Funding, or Conflicts of Interest reads as not ready, even when the science is fine.

Manuscript structure: Cancers expects a defined section set: Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusions, plus the declarations block. Original research and systematic reviews need a structured abstract of around 250 words under Background/Objectives, Methods, Results, and Conclusions headings. The abstract is the first thing the pre-check editor reads, so the cancer question and the main result both need to be visible there.

Reporting and methods readiness: Provide full experimental detail so results can be reproduced, and follow the design-appropriate guideline: CONSORT for randomized trials, PRISMA for systematic reviews and meta-analyses (with a registered protocol), REMARK for tumor-marker prognostic studies, ARRIVE for animal work. A clinical or translational paper that does not map cleanly onto its reporting checklist is the most common reviewer-stage friction point.

Declarations and ethics: Draft the Institutional Review Board statement, Informed Consent statement, Author Contributions (by initials), Funding, Data Availability, and Conflicts of Interest sections before you upload. These are not post-acceptance paperwork at MDPI; they are pre-check gates.

Figures, supplementary, and abstract assets: A graphical abstract is optional but commonly used; if supplied, it should be a high-resolution PNG, JPEG, or TIFF. Supplementary materials should carry the detail that would slow the main narrative. ORCID is expected for the submitting author, and the system will ask for suggested reviewers.

In our pre-submission review work with Cancers submissions, three failure patterns generate the most consistent pre-check returns and reviewer friction, and they are testable against your own manuscript before you upload.

Across our oncology pre-submission reviews, the pattern that surprises authors most is that the Cancers pre-check is not a quality filter in the Nature sense; it is a completeness-and-fit filter. The manuscripts that get returned fastest are rarely bad science. They are competent studies whose declarations block, scope angle, or reporting compliance is not ready for a fast, template-driven screen. Manuscripts coming through pre-submission review for Cancers split cleanly along these three lines.

Scope-thin oncology framing that the section editor cannot place

The single most common pattern we see is a manuscript whose cancer relevance is downstream rather than central. The study is really a cell-biology, immunology, bioinformatics, or methods paper, and a cancer cell line or a TCGA dataset has been added so the work can target an oncology journal. Cancers is section-based and organized by oncology subfield, so the pre-check editor has to place the manuscript in a specific section.

When the cancer question is not the actual subject, the section assignment fails and the paper is returned or redirected fast. The testable version of this failure: read your own abstract and introduction, and ask whether a section editor could name the oncology subfield from the first paragraph alone.

If the cancer angle only appears in the discussion, or only as a future application, the framing is too thin for the pre-check, and the fix is to rebuild the introduction and abstract around the cancer question rather than around the method.

Check whether your Cancers scope angle reads as oncology from the abstract →

Incomplete ethics, consent, and data-availability declarations

The second pattern is a declarations block that is missing, generic, or left as stub text. MDPI treats the Institutional Review Board statement, Informed Consent statement, animal-ethics statement, and Data Availability Statement as pre-check gates, not as paperwork to finalize after acceptance.

We repeatedly see human-subjects oncology studies with no IRB approval number, retrospective chart-review studies with no consent or waiver language, and a Data Availability Statement that reads only "data available on request" with no repository, accession, or concrete access route. Because the pre-check is fast, a single missing statement can return the manuscript before review.

The testable version: for every claim in your paper that touches patients, tissue, or animals, confirm there is a corresponding ethics statement with a real approval identifier, and confirm your Data Availability Statement names where the data actually lives.

Check whether your Cancers declarations block is complete for pre-check →

Reporting that does not map onto its guideline checklist

The third pattern shows up at the reviewer stage rather than pre-check, and it is reporting that does not follow the checklist matching the study design.

A randomized trial that does not supply a CONSORT flow diagram, a systematic review with no PRISMA diagram and no registered protocol, a prognostic tumor-marker study that ignores REMARK, or animal work that omits ARRIVE items: each one forces reviewers to spend their attention on missing structure rather than on the science. In oncology, where clinical relevance hangs on how endpoints, sample sizes, and statistical analyses are reported, this is the highest-leverage fix before submission.

The testable version: identify the guideline that matches your design, walk your manuscript against every checklist item, and supply the completed checklist and the relevant diagram in the supplementary files. If half your checklist items point to "see Methods" without the Methods actually covering them, the reporting is not ready.

Check whether your Cancers reporting matches its guideline checklist →

Each of these is something you can check against your own draft before you commit the submission. This guide tells you what Cancers editors look for; the review tells you whether YOUR paper passes the pre-check before you upload. We have reviewed 80+ manuscripts targeting oncology journals, including Cancers and its open-access peers. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Run a Cancers submission package check to see whether your scope framing, declarations block, and reporting compliance will clear the MDPI pre-check.

Cancers reports a median first decision near 19 days and median acceptance-to-publication near 2.6 days. Treat these as planning ranges, not promises: clinical and large translational manuscripts often run longer because reviewer search takes time in specialized subfields.

• Day 0: Submission via SuSy. The portal accepts the package and routes it to the section editor for pre-check.

• Days 1 to 3: Editorial pre-check. The editor screens scope fit, ethics completeness, integrity and plagiarism checks, and basic soundness.

The fastest returns happen here, before any reviewer is invited.

• Days 3 to 7: Reviewer invitation. Manuscripts that pass pre-check enter single-blind reviewer search, typically targeting two or more reviewers in the relevant oncology subfield.

• Days 7 to 19: Peer review and first decision. Reviewer reports return and the editor issues the first decision, with a median near 19 days from submission.

Major revision is the most common outcome for papers that clear pre-check.

• Days 19 to 35: Revision and acceptance. Revisions are usually requested on a short clock; resubmission and a second review cycle commonly land acceptance inside a few weeks for in-scope, complete packages.

• Days 35 to 40: Production and publication. Acceptance to publication runs near 2.6 days at median, so the slow part of the calendar is reviewer search and revision, not production.

This guide was researched and built from primary sources: the sources we checked include the Cancers Instructions for Authors, the journal's aims-and-scope and editorial-process pages, MDPI's research and publication ethics policy, and Manusights pre-submission review patterns from oncology manuscripts deciding between Cancers and peer open-access oncology journals. We reviewed and compared current MDPI author guidance with recent Manusights work reviews from authors weighing Cancers, Cancer Medicine, BMC Cancer, and Frontiers in Oncology. Last reviewed by the Manusights oncology editorial team on 2026-06-06.

Source limitations: MDPI can update APC, article-format details, abstract caps, and editorial-process numbers after this review date, so verify final administrative details against the official Cancers author pages before upload. Median timelines are reported by the journal and vary by subfield. Use this guide for the decision the official instructions cannot answer: whether your scope framing, declarations block, and reporting compliance are ready for the MDPI pre-check.

• Best oncology journals
• Cancer Cell submission guide
• Lancet Oncology submission guide
• Rejected from Journal of Clinical Oncology, where next?
• Journal of Clinical Oncology journal metrics

Before you upload, run your manuscript through a Cancers submission readiness check to catch the scope, ethics, and reporting gaps the MDPI pre-check filters for. The check is free to run (/ai-review) and takes a single upload.